Purpura Treatment Market Information, by type (nonthrombocytopenic, thrombocytopenic) by drugs (corticosteroids, intravenous immunoglobulin (ivig), romiplostim (nplate), eltrombopag (promacta)) - Forecast to 2022
ID: MRFR/Pharma/1210-HCR | February 2021 | Region: Global | 80 pages
Study objectives of the Purpura Treatment Market:
- To provide detailed analysis of the market structure along with forecast for the next 7 years of the various segments and sub-segments of the purpura treatment market
- To provide insights about factors affecting the market growth
- To analyze the market based on various factors- price analysis, supply chain analysis, porters five force analysis etc.
- To provide historical and forecast revenue of the market segments and sub-segments with respect to the main geography and various regions globally.
- To provide regional level analysis of the market with respect to the current market size and future prospective
- To provide regional level analysis of the market for segments by type, by drugs and its sub-segments.
- To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market
- To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the global purpura treatment market.
Purpura treatment market, by Region
Intended Audience
- Pharmaceutical manufacturers & Suppliers
- Purpura treatment products manufacturers & Suppliers
- Pharmaceutical and biotechnology companies
- Hospitals and diagnostic centers
- Clinics
- Academic research institutes
- Government institutes
Market Synopsis of Purpura treatment Market:
Market Scenario:
The globally market for purpura treatment is one of the steady growing markets. Purpura occurs when the blood vessels and blood pools under the human skin, result in purple spots on the skin. There are various causes for purpura disease such as disorders that affect blood clotting, weak blood vessels, inflammation in the blood vessels, telangiectasia or Ehlers-Danlos syndrome. Globally the market for purpura treatment is expected to grow at the rate of about XX% from 2016 to 2022.
Key Finding
- The purpura treatment global market is expected to reach $XX million by 2022.
- Corticosteroid holds the largest share of XX% of the purpura treatment market.
- North America holds the largest market share of XX% of purpura treatment’s and is expected to reach $XX billion by the end of forecast period.
- Asia Pacific is expected to be the fastest growing market at a CAGR of XX%
Segments:
Purpura treatment market has been segmented on the basis of type which comprises of nonthrombocytopenic and thrombocytopenic. On the basis of drugs, the market is segmented into Corticosteroids, Intravenous immunoglobulin (IVIG), romiplostim (Nplate), eltrombopag (Promacta) and others.
Regional Analysis of Purpura treatment Market:
Globally North America is the largest market for purpura treatment market. The North American market for purpura treatment is expected to grow at a CAGR of XX% and is expected to reach at US$ XXX Million by the end of the forecasted period. Europe is the second-largest market for purpura treatment which is expected to grow at a CAGR of XX%. Asia pacific region is expected to be fastest growing region in purpura treatment market.
Key Players for Purpura treatment Market:
Some of the key players in this market are: Bristol-Myers Squibb Company, Pfizer Inc., GlaxoSmithKline Plc., Novartis AG, Hovione, Sanofi Winthrop Industrie S.A., Hoffman-L Roche, Amgen Inc and Grifols Biologicals Inc, and others.
The report for Purpura treatment market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions
Frequently Asked Questions (FAQ) :
High prevalence and rising per-capita healthcare expenditure are major tailwinds pushing the growth of the global purpura treatment market.
Stringent government regulations and the lack of awareness about the conditions are major growth impeders for the global purpura treatment market.
North America holds the largest share in the global purpura treatment market, followed by Europe and the Asia Pacific, respectively.
Bristol-Myers Squibb Company (U.S.), GlaxoSmithKline Plc. (U.S.), Pfizer Inc. (U.S.), Novartis AG (Switzerland), Sanofi Winthrop Industrie (U.S.), Hovione (Portugal), F. Hoffman-La Roche AG (Switzerland), Grifols Biologicals Inc. (U.S.), and Amgen Inc. (U.S.), are some of the top players operating in the global purpura treatment market.
Strategic initiatives such as mergers & acquisitions, collaborations, expansion, and technology/ product launch are some of the growth strategies that players operating in the global Purpura treatment market adopt to gain a larger competitive advantage.
1 Report Prologue
2 Market Introduction
2.1 Introduction
2.2 Scope of Study
2.3 Research Objective
2.4 Assumptions & Limitations
2.4.1 Assumptions
2.4.2 Limitations
3 Research Methodology
3.1 Research Process
3.2 Primary Research
3.3 Secondary Research
4 Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Challenges
4.4 Opportunities
5 Market Factor Analysis
5.1 Porter’s Five Forces Model
5.1.1 Bargaining power of suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Supply Chain Analysis
6 Global Purpura Treatment Market, By Type
6.1 Non-thrombocytopenic Purpura
6.2 Thrombocytopenic Purpura
6.3 Allergic Purpura
7 Global Purpura Treatment Market, By Cases
7.1 Acute
7.2 Chronic
8. Global Purpura Treatment Market, By Treatment
8.1 Corticosteroids
8.2 Intravenous Iimmunoglobulin
8.3 Other Drug Therapies
8.3.1 Romiplostim (Nplate)
8.3.2 Eltrombopag (Promacta)
9 Global Purpura Treatment Market, By Regions
9.1 Americas
9.1.1 North America
9.1.1.1 U.S.
9.1.1.2 Canada
9.1.2 South America
9.2 Europe
9.2.1 Western Europe
9.2.1.1 Germany
9.2.1.2 France
9.2.1.3 UK
9.2.1.4 Italy
9.2.1.5 Spain
9.2.1.6 Rest of Western Europe
9.2.2 Eastern Europe
9.3 Asia Pacific
9.3.1 Japan
9.3.2 China
9.3.3 India
9.3.4 Australia
9.3.5 Republic of Korea
9.3.6 Rest of Asia-Pacific
9.4 Middle East & Africa
9.4.1 UAE
9.4.2 Saudi Arabia
9.4.3 Qatar
9.4.4 Rest of Middle East & Africa
10 Competitive Landscape
10.1 Company Share Analysis
10.2 Key Development Landscape
10.2.1 Mergers & Acquisitions
10.2.2 Partnerships & Agreements
10.2.3 New Product Launch
10.2.4 Others
11 Company Profile
11.1 Amgen Inc
11.1.1 Company Overview
11.1.2 Product/Business Overview
11.1.3 Financial Overview
11.1.4 Key Developments
11.2 Bristol-Myers Squibb Company
11.2.1 Company Overview
11.2.2 Product overview
11.2.3 Financial Overview
11.2.4 Key Developments
11.3 F. Hoffman-La Roche
11.3.1 Company Overview
11.3.2 Product Overview
11.3.3 Financial Overview
11.3.4 Key Development
11.4 GlaxoSmithKline Plc.
11.4.1 Company Overview
11.4.2 Product Overview
11.4.3 Financial Overview
11.4.4 Key Developments
11.5 Grifols Biologicals Inc
11.5.1 Company Overview
11.5.2 Product overview
11.5.3 Financial Overview
11.5.4 Key Developments
11.6 Hovione
11.6.1 Company Overview
11.6.2 Product Overview
11.6.3 Financial Overview
11.6.4 Key Developments
11.7 Novartis AG
11.7.1 Company Overview
11.7.2 Product Overview
11.7.3 Financial Overview
11.7.4 Key Developments
11.8 Pfizer Inc.
11.8.1 Company Overview
11.8.2 Product Overview
11.8.3 Financial Overview
11.8.4 Key Developments
11.9 Sanofi
11.9.1 Company Overview
11.9.2 Product Overview
11.9.3 Financial Overview
11.9.4 Key Developments
12 Bibliography
